MLTX Stock Overview
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MoonLake Immunotherapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.77 |
| 52 Week High | US$64.98 |
| 52 Week Low | US$24.31 |
| Beta | 1.28 |
| 1 Month Change | -7.15% |
| 3 Month Change | -34.77% |
| 1 Year Change | 51.22% |
| 3 Year Change | 308.52% |
| 5 Year Change | n/a |
| Change since IPO | 288.66% |
Recent News & Updates
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14
MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26Recent updates
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Shareholder Returns
| MLTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | 0.4% | 1.0% |
| 1Y | 51.2% | 5.4% | 27.2% |
Return vs Industry: MLTX exceeded the US Biotechs industry which returned 3% over the past year.
Return vs Market: MLTX exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| MLTX volatility | |
|---|---|
| MLTX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MLTX's share price has been volatile over the past 3 months.
Volatility Over Time: MLTX's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 50 | Jorge da Silva | www.moonlaketx.com |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics Fundamentals Summary
| MLTX fundamental statistics | |
|---|---|
| Market cap | US$2.62b |
| Earnings (TTM) | -US$40.68m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-63.0x
P/E RatioIs MLTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.68m |
| Earnings | -US$40.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLTX perform over the long term?
See historical performance and comparison